ALFA Finder| Revenue growth | Q2 +18.9% YoY; H1 +24.4% YoY |
|---|---|
| Margins | EBITDA margin 7.3% vs 8.8% YoY; up 365bps QoQ |
| Demand visibility | Star Product 1 order secured in developed markets |
| Management confidence | Qualitative optimism; no quantified targets |
Growth
Export revenue +24.7% YoY to ₹908 Mn; innovative products +84% YoY to ₹149 Mn. H1 operating income +24.4%.
Outlook
No numeric guidance. One-time EU-GMP costs not fully recurring in H2; Q3 FY27 EU response in progress.
Risks
EBITDA down 1.2% YoY; H1 PAT loss ₹61 Mn vs ₹23 Mn. Pending EU-GMP re-certification limits developed-market revenue.
Last quarter's promises, checked
Delivered
- Guided FY27 growth 10-15% ex-EU → H1 op income +24.4% YoY (= BEAT)
Partly delivered
- Guided 8-10 MAs post EU-GMP → 4 MAs in Q2 pre-certification (= PARTIAL)
Missed
- Guided EU-GMP report in 1-2 wks, cert by Q4 → CAPA still under review, no cert (= MISS)
- Guided FY27 margin ~last year → Q2 7.3% vs 8.8% YoY (= MISS)
- Guided one-time costs not repeating → EU-GMP costs still weighing in Q2 (= MISS)
Investor Presentation filed with NSE, NSE: ZIMLAB. Summary written with AI assistance from the document.
Zim Laboratories Ltd: key numbers
- Share price
- ₹141.00
- Market cap
- ₹756.6 Cr
- Revenue (annual)
- ₹374.4 Cr
- Net profit (annual)
- ₹5.84 Cr
- P/E (TTM)
- 365.3×Sector 43.8×
- Promoter holding
- 30.30%-0.06% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zim Laboratories Ltd
All →Zim Laboratories Q2 FY27 Results: Net Loss of ₹2 Cr, Loss Widens
Zim Laboratories Ltd reported revenue from operations of ₹105.4 Cr (+18.8% YoY) and a net loss of ₹2 Cr for Q2 FY27.
- Key figure
- Net loss ₹2 Cr
Zim Laboratories Board Meeting Date
Zim Laboratories has scheduled a board meeting on 4 November 2026 to consider its unaudited quarterly results for the quarter ended 30 September 2026. The trading window stays closed from 1 October to 6 November 2026.
Zim Laboratories Regulatory Approval
Zim Laboratories received TGA GMP certification from Australia's Therapeutic Goods Administration for its Nagpur manufacturing facility. The certification covers various dosage forms and is valid until June 2028.
- From
- Therapeutic Goods Administration (TGA), Australia
Zim Laboratories Credit Rating
CARE Ratings has reaffirmed the credit ratings of Zim Laboratories Limited for its bank facilities, revising the outlook on long-term facilities to negative.
Zim Laboratories Other Announcement
Zim Laboratories Limited filed a certificate confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Zim Laboratories Merger & Restructuring Worth ₹1,404,640 Cr
ZIM Laboratories completed incorporation of its wholly-owned Chilean subsidiary, ZIM Laboratories SpA. The LATAM expansion entity is now operational, marking completion of the February 2026 board-approved plan.
- Value
- ₹14,04,640 Cr